HypnoVR, a Strasbourg, France-based developer of virtual reality-based medical hypnosis solutions to manage pain and stress, secured €700k in seed funding.
The round was led by Guillaume Richard, founder and chairman of OuiCare, Daniel Caille, founder and chairman at Vivalto Santé Holding and La Javaness, startup accelerator specialized in AI, with participation from Bpifrance, the French public investment bank, and business angels Maurice Berenger, CEO of CardioRenal, Guy Paillaud, president of the family office Financière de l’Intendance, and Jérôme Dillard, former CEO of TF1 Shopping, former managing director of B2S and former head of diversifications at M6 among others.
This funding, a combination of cash and work for equity investment, will enable the company to pursue product development and reinforce its sales and marketing team.
Co-founded by Dr. Denis Graff, Dr. Chloé Chauvin, and Nicolas Schaettel, president, HypnoVR provides virtual reality software that enables large-scale deployment of medical hypnosis for managing pain, stress and anxiety.
In September 2018, the company will bring to market its medical hypnosis virtual reality solution. Using commercially available virtual reality headsets such as Oculus Rift or Samsung Gear, the solution places the patient into an intense multisensory tridimensional immersion experience. The technology, which is in the final stages of obtaining a class 1 medical device CE marking, is currently being used in applications for pediatric surgery, gastroenterology, gynecology and dental surgery.